Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice

Ritchie, Leona A ORCID: 0000-0002-0392-1767, Qin, Shuguang, Penson, Peter E ORCID: 0000-0001-6763-1489, Henney, Neil C ORCID: 0000-0002-2834-1566 and Lip, Gregory YH ORCID: 0000-0002-7566-1626 (2020) Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice. FUTURE CARDIOLOGY, 16 (6). pp. 585-596. ISSN 1479-6678, 1744-8298

Access the full-text of this item by clicking on the Open Access link.

Abstract

Vernakalant is an intravenous anti-arrhythmic drug available in Europe, Canada and some countries in Asia for the restoration of sinus rhythm in acute onset atrial fibrillation. Currently, it is not available in USA because the US FDA have ongoing concerns about its safety. Vernakalant has a unique pharmacological profile of multi-ion channel activity and atrial-specificity that distinguishes it from other anti-arrhythmic drugs. This is thought to enhance efficacy but there are concerns of adverse events stemming from its diverse pharmacology. This ambiguity has prompted a review of the available clinical evidence on efficacy and safety to help re-evaluate its place in clinical practice.

Item Type:	Article
Uncontrolled Keywords:	anti-arrhythmic drugs, atrial fibrillation, cardioversion, rhythm control, vernakalant
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User:	Symplectic Admin
Date Deposited:	06 Jul 2021 08:30
Last Modified:	07 Dec 2024 12:31
DOI:	10.2217/fca-2020-0039
Open Access URL:	https://researchonline.ljmu.ac.uk/id/eprint/12861/
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3128976